JP2013526582A - 癌治療 - Google Patents

癌治療 Download PDF

Info

Publication number
JP2013526582A
JP2013526582A JP2013511383A JP2013511383A JP2013526582A JP 2013526582 A JP2013526582 A JP 2013526582A JP 2013511383 A JP2013511383 A JP 2013511383A JP 2013511383 A JP2013511383 A JP 2013511383A JP 2013526582 A JP2013526582 A JP 2013526582A
Authority
JP
Japan
Prior art keywords
cells
vaccine
cancer
patients
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013511383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526582A5 (enExample
Inventor
ポダック，エックハルト，アール．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of JP2013526582A publication Critical patent/JP2013526582A/ja
Publication of JP2013526582A5 publication Critical patent/JP2013526582A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013511383A 2010-05-21 2011-05-20 癌治療 Pending JP2013526582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34733610P 2010-05-21 2010-05-21
US61/347,336 2010-05-21
PCT/US2011/037327 WO2011146828A2 (en) 2010-05-21 2011-05-20 Cancer treatment

Publications (2)

Publication Number Publication Date
JP2013526582A true JP2013526582A (ja) 2013-06-24
JP2013526582A5 JP2013526582A5 (enExample) 2014-07-24

Family

ID=44972662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511383A Pending JP2013526582A (ja) 2010-05-21 2011-05-20 癌治療

Country Status (9)

Country Link
US (1) US20110287057A1 (enExample)
EP (1) EP2571522A4 (enExample)
JP (1) JP2013526582A (enExample)
KR (1) KR20130113953A (enExample)
CN (1) CN102883746A (enExample)
AU (1) AU2011255463A1 (enExample)
CA (1) CA2837059A1 (enExample)
IL (1) IL222958A0 (enExample)
WO (1) WO2011146828A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509888A (ja) * 2015-02-06 2018-04-12 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
JP2021505138A (ja) * 2017-12-04 2021-02-18 ヒート バイオロジクス，インコーポレイテッド 細胞に基づくワクチンの製造

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
CN103372209B (zh) * 2012-04-24 2014-09-17 中国科学院微生物研究所 gp96蛋白的抗体在制备癌细胞抑制剂中的应用
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030136A2 (en) * 2003-09-26 2005-04-07 University Of Miami Tumor vaccine
WO2009114085A2 (en) * 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006413A1 (en) * 2000-01-27 2002-01-17 Sobol Robert E. Genetically engineered tumor cell vaccines
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030136A2 (en) * 2003-09-26 2005-04-07 University Of Miami Tumor vaccine
WO2009114085A2 (en) * 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015016224; Ｊｏｕｒｎａｌ　ｏｆ　Ｔｈｏｒａｃｉｃ　Ｏｎｃｏｌｏｇｙ ２（８）, 2007, Ｓ１９７-８ *
JPN6015016225; Ｂｒ　Ｊ　Ｃａｎｃｅｒ ５５（５）, 1987, ５１３-６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509888A (ja) * 2015-02-06 2018-04-12 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
JP2021505138A (ja) * 2017-12-04 2021-02-18 ヒート バイオロジクス，インコーポレイテッド 細胞に基づくワクチンの製造

Also Published As

Publication number Publication date
AU2011255463A1 (en) 2012-11-01
EP2571522A4 (en) 2013-11-20
CA2837059A1 (en) 2011-11-24
WO2011146828A3 (en) 2012-03-15
CN102883746A (zh) 2013-01-16
EP2571522A2 (en) 2013-03-27
WO2011146828A2 (en) 2011-11-24
KR20130113953A (ko) 2013-10-16
US20110287057A1 (en) 2011-11-24
IL222958A0 (en) 2013-02-03

Similar Documents

Publication Publication Date Title
JP2013526582A (ja) 癌治療
Baharom et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
JP5239041B2 (ja) 癌の治療剤
US7951365B2 (en) Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP1225870B1 (en) Composition and method of cancer antigen immunotherapy
US8007785B2 (en) Method for treating colon cancer with tumour-reactive T-lymphocytes
JP2022092001A (ja) 樹状細胞免疫療法
JP2020514324A (ja) 腫瘍溶解性ウイルス療法
Medler et al. Defining immunogenic and radioimmunogenic tumors
WO2014161887A1 (en) Targeted cancer immune therapy
Tamir et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors
Chakravarty et al. Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy
Konduri et al. Chemo-immunotherapy mediates durable cure of orthotopic K ras G12D/p53−/− pancreatic ductal adenocarcinoma
Plautz et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma
Niavarani et al. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer
Sivendran et al. Herpes simplex virus oncolytic vaccine therapy in melanoma
US20040057935A1 (en) Intratumoral delivery of dendritic cells
Viehl et al. A Tat Fusion Protein–Based Tumor Vaccine for Breast Cancer
BR112014017819B1 (pt) Método de produzir células cancerígenas imunogênicas isoladas
WO2020069454A1 (en) Treatment methods
Santin et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer
Chen et al. Interleukin‑15: A potent adjuvant enhancing the efficacy of an autologous whole‑cell tumor vaccine against Lewis lung carcinoma
JPH09504786A (ja) ハプロタイプ適合サイトカイン分泌細胞および免疫応答を刺激するための使用方法
JP5079962B2 (ja) ＴＧＦβ阻害剤を発現する遺伝的に改変された細胞であって、肺癌細胞である細胞
US20100143257A1 (en) Prevention of Cancers by Immunization

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160112